Abstract
The concept of a pharmacokinetics–pharmacodynamics (PK/PD) assessment of drug development candidates is well established in pharmaceutical research and development, and PK/PD modeling is common practice in all pharmaceutical companies. A recent analysis (Morgan et al., Drug Discov Today 17(9–10):419–424, 2012) revealed however that insufficient certainty in the integrity of the causal chain of fundamental pharmacological steps from drug dosing through systemic exposure, target tissue exposure, and engagement of molecular target to pharmacological response is still the major driver of failure in phase II of clinical drug development. Despite the rise of molecular biomarkers, ethical, scientific, and practical constraints very often still prevent a direct assessment of each necessary step ultimately leading to an intended drug effect or an unintended adverse reaction. Yet, incomplete investigation of the causality of drug responses is a major risk for translational assessments and the prediction of drug responses in different species or other populations. Mechanism-based modeling and simulation (M&S) offers a means to investigate complex physiological and pharmacological processes and to complement experimental data for non-accessible steps in the pharmacological causal chain. With the help of two examples, it is illustrated, what level of physiological detail, state-of-the-art models can represent, how predictive these models are and how mechanism-based approaches can be combined with empirical correlation-based concepts.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Cartwright ME et al (2010) Proof of concept: a PhRMA position paper with recommendations for best practice. Clin Pharmacol Ther 87:278–285
Cohen A (2008) Pharmacokinetic and pharmacodynamic data to be derived from early-phase drug development-designing informative human pharmacological studies. Clin Pharmacokinet 47:373–381
US Food and Drug Administration (1999) Guidance for industry: population pharmacokinetics, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), February 1999
Edginton AN, Schmitt W, Willmann S (2006) Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clin Pharmacokinet 45(10):1013–1034
Eissing T, Kuepfer L, Becker C, Block M, Coboeken K, Gaub T, Goerlitz L, Jaeger J, Loosen R, Ludewig B, Meyer M, Niederalt C, Sevestre M, Siegmund HU, Solodenko J, Thelen K, Telle U, Weiss W, Wendl T, Willmann S, Lippert J (2011) A computational systems biology software platform for multiscale modeling and simulation: integrating whole-body physiology, disease biology, and molecular reaction networks. Front Physiol 2:4
El-Khatib FH, Russell SJ, Nathan DM, Sutherlin RG, Damiano ER (2010) A bihormonal closed-loop artificial pancreas for type 1 diabetes. Sci Transl Med 2:27ra27
Empfield JR, Leeson PD (2010) Lessons learned from candidate drug attrition. IDrugs 13:869–887
Ette EI, Williams PJ (2004) Population pharmacokinetics I: background, concepts, and models. Ann Pharmacother 38(10):1702–1706
European Medicines Agency (2007) Guideline on reporting the results of population pharmacokinetic analyses. European Medicines Agency, June 2007
Gabrielsson J et al (2011) Pharmacodynamic–pharmacokinetic integration as a guide to medicinal chemistry. Curr Top Med Chem 11:404–418
Geanacopoulos M, Barratt R (2015) How the critical path initiative addresses CDER’s regulatory science needs some illustrative examples. Ther Innov Regul Sci, January 29, 2015
Hodgkin AL, Huxley AF (1952) Propagation of electrical signals along giant nerve fibres. Proc R Soc Lond B Biol Sci 140(899):177–183
Kobayashi M, Chisaki I, Narumi K, Hidaka K, Kagawa T, Itagaki S, Hirano T, Iseki K (2008) Association between risk of myopathy and cholesterol-lowering effect: a comparison of all statins. Life Sci 82(17):969–975
Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R (2008) SLCO1B1 variants and statin-induced myopathy – a genomewide study. N Engl J Med 359(8):789–799
Lippert J, Brosch M, von Kampen O, Meyer M, Siegmund HU, Schafmayer C, Becker T, Laffert B, Görlitz L, Schreiber S, Neuvonen PJ, Niemi M, Hampe J, Kuepfer L (2012) A mechanistic, model‐based approach to safety assessment in clinical development. CPT Pharmacometrics Syst Pharmacol 1(11):1–8
Morgan P, Van Der Graaf PH, Arrowsmith J, Feltner DE, Drummond KS, Wegner CD, Street SD (2012) Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discov Today 17(9-10):419–424
Niemi M, Pasanen MK, Neuvonen PJ (2011) Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 63(1):157–181
Paul SM et al (2010) How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov 9:203–214
Romero K, Sinha V, Allerheiligen S, Danhof M, Pinheiro J, Kruhlak N, Wang Y, Wang SJ, Sauer JM, Marier JF, Corrigan B, Rogers J, Lambers Heerspink HJ, Gumbo T, Vis P, Watkins P, Morrison T, Gillespie W, Gordon MF, Stephenson D, Hanna D, Pfister M, Lalonde R, Colatsky T (2013) Modeling and simulation for medical product development and evaluation: highlights from the FDA-C-Path-ISOP 2013 workshop. J Pharmacokinet Pharmacodyn 41(6):545–552
Schaller S, Willmann S, Lippert J, Schaupp L, Pieber TR, Schuppert A, Eissing T (2013) A generic integrated physiologically based whole‐body model of the glucose‐insulin‐glucagon regulatory system. CPT Pharmacometrics Syst Pharmacol 2(8):1–10
Schuck E, Bohnert T, Chakravarty A, Damian-Iordache V, Gibson C, Hsu CP, Heimbach T, Krishnatry AS, Liederer BM, Lin J, Maurer T, Mettetal JT, Mudra DR, Nijsen MJ, Raybon J, Schroeder P, Schuck V, Suryawanshi S, Su Y, Trapa P, Tsai A, Vakilynejad M, Wang S, Wong H (2015) Preclinical pharmacokinetic/pharmacodynamic modeling and simulation in the pharmaceutical industry: an IQ consortium survey examining the current landscape. AAPS J 17(2):462–473
Sistonen J, Sajantila A, Lao O et al (2007) CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics 17(2):93–101
Sorger PK, Allerheiligen SR, Abernethy DR, Altman RB, Brouwer KL, Califano A, D’Argenio DZ, Iyengar R, Jusko WJ, Lalonde R, Lauffenburger DA, Shoichet B, Stevens JL, Subramaniam S, Van der Graaf P, Ward R (2011) Quantitative and systems pharmacology in the post-genomic era: new approaches to discovering drugs and understanding therapeutic mechanisms. In: An NIH white paper by the QSP workshop group. NIH, Bethesda, pp 1–48
Wagner C, Pan Y, Hsu V, Grillo JA, Zhang L, Reynolds KS, Sinha V, Zhao P (2015) Predicting the effect of cytochrome P450 inhibitors on substrate drugs: analysis of physiologically based pharmacokinetic modeling submissions to the US food and drug administration. Clin Pharmacokinet 54(1):117–127
Willmann S, Lippert J, Schmitt W (2005) From physicochemistry to absorption and distribution: predictive mechanistic modelling and computational tools. Expert Opin Drug Metab Toxicol 1(1):159–168
Willmann S, Höhn K, Edginton A, Sevestre M, Solodenko J, Weiss W, Lippert J, Schmitt W (2007) Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J Pharmacokinet Pharmacodyn 34(3):401–431
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Lippert, J. et al. (2015). Modeling and Simulation of In Vivo Drug Effects. In: Nielsch, U., Fuhrmann, U., Jaroch, S. (eds) New Approaches to Drug Discovery. Handbook of Experimental Pharmacology, vol 232. Springer, Cham. https://doi.org/10.1007/164_2015_21
Download citation
DOI: https://doi.org/10.1007/164_2015_21
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-28912-0
Online ISBN: 978-3-319-28914-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)